NIH R01 · 2024
Targeting SUMO1 degradation for advanced colon cancer therapy
Project Summary/Abstract The advanced colon cancer with organ invasion and liver metastasis are the most common cause of colon cancer death in part due to the resistance to current standard therapies. The ultimate goal of this project is to develop small-molecule degraders of small ubiquitin-related modifier 1 (SUMO1) as the first-in-class anticancer drugs for treatment of advanced colon cancers. To achieve this goal, we have already identified SUMO1 as a cancer drug target, developed cancer cell-based drug screen, identified the hit compound, and optimized the more potent lead compounds through chemical modification of the hit compound. Investigating the drug-targeted pathway, we have…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.